Valuation
- Market cap
- 489,583,000
- Revenue TTM
- $0
- Net income TTM
- $-61,975,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 401,300
- Avg volume
- —
- Day's range
- $7.20 – $8.10
- Shares out
- 62,767,000
- Stochastic %K
- 40%
- Beta
- —
- Analysts
- Strong Buy
- Price target
- $33.50
Company profile
Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company develops therapies that targets signal regulatory proteins for the treatment of novel targets for treatment of immune-mediated diseases and cancer. Its lead product candidate is ipsoprubart, that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, treatment for seconda...
Show more
Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company develops therapies that targets signal regulatory proteins for the treatment of novel targets for treatment of immune-mediated diseases and cancer. Its lead product candidate is ipsoprubart, that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, treatment for secondary hemophagocytic lymphohistiocytosis and T/NK Cell Malignancies; ELA822, a novel SIRP-specific monoclonal antibody for deplete activated T cells, treatment for T cell mediated immune disorders. Electra Therapeutics, Inc. was incorporated in 2018 and is based in South San Francisco, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- (888) 743-2290
- Website
- https://electra-therapeutics.com
- Address
- 230 E Grand Avenue, Suite S-100, South San Francisco, United States
Latest news
No headlines yet.
